YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase
about
Human soluble guanylate cyclase: functional expression and revised isoenzyme familyNO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVSHeme-dependent and independent soluble guanylate cyclase activators and vasodilation.YD-3, a novel inhibitor of protease-induced platelet activationSensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzymeNew oxadiazole derivatives showing partly antiplatelet, antithrombotic and serotonin antagonistic properties.NO-independent regulatory site on soluble guanylate cyclase.Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclaseProtective effects of YC-1 against glutamate induced PC12 cell apoptosis.Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by nonheme nitric oxide, ATP, and GTPInhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy.Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects.Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from ratYC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea.Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studiesPharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studiesKMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channelsYC-1 increases cyclo-oxygenase-2 expression through protein kinase G- and p44/42 mitogen-activated protein kinase-dependent pathways in A549 cells.NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.Cyclic nucleotide signalling in kidney fibrosis.The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cellsPlatelets, atherosclerosis and the endothelium: new therapeutic targets?YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia.Natriuretic peptides and therapeutic applications.YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathwayNovel therapies for cyclic GMP control of vascular smooth muscle growthStimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Stimulators of soluble guanylyl cyclase: future clinical indicationsThe chemistry and biology of soluble guanylate cyclase stimulators and activators.Surface plasmon resonance using the catalytic domain of soluble guanylate cyclase allows the detection of enzyme activatorsNitric oxide regulates antagonistically phagocytic and neurite outgrowth inhibiting capacities of microglia.Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines.Guanylate cyclase activator YC-1 enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells via activation of apoptosis-related proteins.YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway.
P2860
Q24314629-C2E1D831-46F9-4738-80D8-F9D481FA0D8DQ24656131-A87ABA35-6CDD-4AB0-9C56-9055FD6AF38BQ24798007-BF36ADED-B186-4069-9DFE-26AF3576CBDEQ27021649-8E0F68C1-871B-40C8-B3CC-65A98C4FA048Q27692662-A6BFEF62-4B3E-4992-A014-ADAB6742487CQ28344498-B4B15DAE-48B6-48B9-9C87-D102C64458A1Q28379416-83EF1AF6-2749-4988-9DEB-19EC5A290D09Q31150145-4F266BA7-8392-4ED2-B4A8-F0C2790711B2Q32165040-44BF20F8-2950-4476-8C36-8AC65DE66A83Q33179221-6CCA42A9-284C-496F-83CF-6D9EF1037267Q33743118-F7DB016F-6EE4-4AEE-9D95-F2758BAC4406Q33948069-D44AB005-CC2D-4A4C-AFB8-B6A408A9670BQ33968322-C6AB3C32-0ADD-47DE-BC22-5ED02215A1D2Q34060673-F23B4033-BE4A-474A-935B-6DD331FFCA04Q34389020-416A0200-CADF-4D07-ADCF-17CEEF993925Q34564998-85C98F52-2257-4EB0-AFE8-F29E17343BABQ34957241-DAA3F8D6-069E-43A2-A80E-9DF96A5CEF9FQ34973860-AB4447CF-808D-40F4-8795-74E158E197D1Q35026974-F6CC9EAA-F5D6-4D8A-850D-EB8EEDC57F3DQ35041586-91B27A15-7A05-4AEB-B2E7-98C2F25D6CDEQ35044037-B7797ACD-8F77-4B22-B20F-BA8184F8B784Q35044042-58737C1C-0DAF-40D1-94CA-CB7577B3FE49Q35044163-1C290192-B1C5-4367-9D35-1ED2D83A6F5AQ35044436-D6BC0066-86D6-44B0-ADCB-BE41F0DBD660Q35044464-BD22422F-0230-4864-9589-14A74EB490DDQ35138860-B964C51F-9B5B-49FD-938A-9FF6E310E0BBQ35188169-83284756-60B6-4902-917F-C25DB2BA3A21Q35570940-E00D4C36-77C6-4ADE-9BBF-EEEF114B78C6Q36052832-566EA195-5F5B-4CA1-96AC-2D53FD456F92Q36794409-CD9634D2-7E95-462A-B843-55757DB423FDQ36964934-6D57495A-C5D8-4CF6-B9CE-062C519DA56AQ37179695-AE75A4BB-C49B-4554-8A9B-9104991EA6C1Q38000562-3076764E-6EF4-4097-9874-07F9304B1EA5Q38093420-9864AA50-0F94-4468-BC78-9573B40A158BQ38130465-AFD6391E-629D-4388-8FC8-D8CCB6D7AAA6Q38646890-832FDC19-2175-46B8-85BC-ED1F6EA306B7Q38844413-AF758B8E-8925-44DE-A6EE-B1E94181FCA7Q39503219-27B315B9-7C90-498D-95BE-BA1237F720BCQ39545932-E0FEFE08-F1B1-42E9-AA12-03B1D7EA25F7Q39672848-CB4550F7-DD24-4CBE-A6EA-53997EDFB9E1
P2860
YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@ast
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@en
type
label
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@ast
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@en
prefLabel
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@ast
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@en
P2093
P2860
P1476
YC-1 inhibited human platelet ...... n of soluble guanylate cyclase
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1995.TB16400.X
P407
P577
1995-10-01T00:00:00Z